Role of Exogenous and Endogenous Hormones in Endometrial Cancer

Review of the Evidence and Research Perspectives

Authors

  • ARSLAN AKHMEDKHANOV,

    Corresponding author
    1. Department of Obstetrics and Gynecology, New York University School of Medicine, New York, New York 10016, USA
    2. Department of Environmental Medicine, New York University School of Medicine, New York, New York 10016, USA
    • Address for correspondence: Dr. Arslan Akhmedkhanov, Department of Obstetrics and Gynecology, New York University School of Medicine, 550 First Avenue, NB 9E2, New York, NY 10016. Voice: 212-263-7763; fax: 212-263-8887; akhmea01@med.nyu.edu.

    Search for more papers by this author
  • ANNE ZELENIUCH-JACQUOTTE,

    1. Department of Environmental Medicine, New York University School of Medicine, New York, New York 10016, USA
    Search for more papers by this author
  • PAOLO TONIOLO

    1. Department of Obstetrics and Gynecology, New York University School of Medicine, New York, New York 10016, USA
    2. Department of Environmental Medicine, New York University School of Medicine, New York, New York 10016, USA
    Search for more papers by this author

Abstract

Endometrial carcinoma is the most common cancer of the female reproductive organs in the United States. International comparisons reveal that the incidence of endometrial cancer vary widely between different countries with the highest rates observed in North America and Northern Europe, intermediate rates in Eastern Europe and Latin America, and lowest rates in Asia and Africa. International variation in endometrial cancer rates may represent differences in the distribution of known risk factors, which include obesity, postmenopausal estrogen replacement, ovarian dysfunction, diabetes mellitus, infertility, nulliparity, and tamoxifen use. Most of the risk factors for endometrial cancer can be explained within the framework of the unopposed estrogen hypothesis, which proposes that exposure to estrogens unopposed by progesterone or synthetic progestins leads to increased mitotic activity of endometrial cells, increased number of DNA replication errors, and somatic mutations resulting in malignant phenotype. Although the impact of exogenous hormone replacement was intensively studied during the last two decades, less is known about the effects of endogenous hormones in endometrial cancer. A review of available experimental, clinical, and epidemiologic data suggests that in addition to estrogens, other endogenous hormones, including progesterone, androgens, gonadotropins, prolactin, insulin, and insulin-like growth factors, may play a role in the pathogenesis of different histopathologic types of endometrial cancer.

Ancillary